A Clinical trial to evaluate the effect of udumbar extract local application in management of healing wound
Phase 2
- Conditions
- Health Condition 1: L80-L99- Other disorders of the skin and subcutaneous tissue
- Registration Number
- CTRI/2024/01/061795
- Lead Sponsor
- Tilak Ayurved Mahavidyalaya pune
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patient having shudha vrana irrespective of age sex occupation
Fresh incised wound,Lacerated Wound will be selected
Uninfected wounds in process of healing will be selected
Exclusion Criteria
Diabetic Wounds
Venous,Tubercular,Ischemic ,Tropical,Neurogenic,malignant ulcers.
Infected Wounds
Patient suffering from HIV , Hbsag
Wounds having dimension more than 6vcm
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Darshan pariksha - akruti,vrana Strav, vran tala, vran gandha, <br/ ><br>2.Sparshan pariksha - Sparshatva, local temperature <br/ ><br>3.Prashna pariksha - daha, Vedan,kanduTimepoint: 3days
- Secondary Outcome Measures
Name Time Method Recurrence of Akruti, vrana strava, vrana tala, vranagandha <br/ ><br>Sparshatva, local temperature, daha, vedana,kanduTimepoint: After 15 days
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie udumbar sara's wound healing effects in L80-L99 skin disorders?
How does udumbar sara compare to ropan taila in promoting epithelialization and granulation tissue formation in shudhha vrana?
Are there specific biomarkers that predict response to udumbar extract in wound healing management?
What are the potential adverse events associated with udumbar sara topical application in skin wound treatment?
What other Ayurvedic compounds or combination therapies show promise in managing L80-L99 skin and subcutaneous tissue disorders?